Cargando…

Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG

A small fraction of recipients who receive polyethylene-glycol (PEG)-containing COVID-19 mRNA-LNP vaccines (Comirnaty and Spikevax) develop hypersensitivity reactions (HSRs) or anaphylaxis. A causal role of anti-PEG antibodies (Abs) has been proposed, but not yet been proven in humans. We used ELISA...

Descripción completa

Detalles Bibliográficos
Autores principales: Kozma, Gergely Tibor, Mészáros, Tamás, Berényi, Petra, Facskó, Réka, Patkó, Zsófia, Oláh, Csaba Zs., Nagy, Adrienne, Fülöp, Tamás Gyula, Glatter, Kathryn Anne, Radovits, Tamás, Merkely, Béla, Szebeni, János
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239905/
https://www.ncbi.nlm.nih.gov/pubmed/37330369
http://dx.doi.org/10.1016/j.vaccine.2023.06.009
_version_ 1785053599415402496
author Kozma, Gergely Tibor
Mészáros, Tamás
Berényi, Petra
Facskó, Réka
Patkó, Zsófia
Oláh, Csaba Zs.
Nagy, Adrienne
Fülöp, Tamás Gyula
Glatter, Kathryn Anne
Radovits, Tamás
Merkely, Béla
Szebeni, János
author_facet Kozma, Gergely Tibor
Mészáros, Tamás
Berényi, Petra
Facskó, Réka
Patkó, Zsófia
Oláh, Csaba Zs.
Nagy, Adrienne
Fülöp, Tamás Gyula
Glatter, Kathryn Anne
Radovits, Tamás
Merkely, Béla
Szebeni, János
author_sort Kozma, Gergely Tibor
collection PubMed
description A small fraction of recipients who receive polyethylene-glycol (PEG)-containing COVID-19 mRNA-LNP vaccines (Comirnaty and Spikevax) develop hypersensitivity reactions (HSRs) or anaphylaxis. A causal role of anti-PEG antibodies (Abs) has been proposed, but not yet been proven in humans. We used ELISA for serial measurements of SARS-CoV-2 neutralizing Ab (anti-S) and anti-PEG IgG/IgM Ab levels before and after the first and subsequent booster vaccinations with mRNA-LNP vaccines in a total of 291 blood donors. The HSRs in 15 subjects were graded and correlated with anti-PEG IgG/IgM, just as the anti-S and anti-PEG Ab levels with each other. The impacts of gender, allergy, mastocytosis and use of cosmetics were also analyzed. Serial testing of two or more plasma samples showed substantial individual variation of anti-S Ab levels after repeated vaccinations, just as the levels of anti-PEG IgG and IgM, which were over baseline in 98–99 % of unvaccinated individuals. About 3-4 % of subjects in the strongly left-skewed distribution had 15–45-fold higher values than the median, referred to as anti-PEG Ab supercarriers. Both vaccines caused significant rises of anti-PEG IgG/IgM with >10-fold rises in about ∼10 % of Comirnaty, and all Spikevax recipients. The anti-PEG IgG and/or IgM levels in the 15 vaccine reactors (3 anaphylaxis) were significantly higher compared to nonreactors. Serial testing of plasma showed significant correlation between the booster injection-induced rises of anti-S and anti-PEG IgGs, suggesting coupled anti-S and anti-PEG immunogenicity. Conclusions: The small percentage of people who have extreme levels of anti-PEG Ab in their blood may be at increased risk for HSRs/anaphylaxis to PEGylated vaccines and other PEGylated injectables. This risk might be further increased by the anti-PEG immunogenicity of these vaccines. Screening for anti-PEG Ab “supercarriers” may help predicting reactors and thus preventing these adverse phenomena.
format Online
Article
Text
id pubmed-10239905
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-102399052023-06-05 Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG Kozma, Gergely Tibor Mészáros, Tamás Berényi, Petra Facskó, Réka Patkó, Zsófia Oláh, Csaba Zs. Nagy, Adrienne Fülöp, Tamás Gyula Glatter, Kathryn Anne Radovits, Tamás Merkely, Béla Szebeni, János Vaccine Article A small fraction of recipients who receive polyethylene-glycol (PEG)-containing COVID-19 mRNA-LNP vaccines (Comirnaty and Spikevax) develop hypersensitivity reactions (HSRs) or anaphylaxis. A causal role of anti-PEG antibodies (Abs) has been proposed, but not yet been proven in humans. We used ELISA for serial measurements of SARS-CoV-2 neutralizing Ab (anti-S) and anti-PEG IgG/IgM Ab levels before and after the first and subsequent booster vaccinations with mRNA-LNP vaccines in a total of 291 blood donors. The HSRs in 15 subjects were graded and correlated with anti-PEG IgG/IgM, just as the anti-S and anti-PEG Ab levels with each other. The impacts of gender, allergy, mastocytosis and use of cosmetics were also analyzed. Serial testing of two or more plasma samples showed substantial individual variation of anti-S Ab levels after repeated vaccinations, just as the levels of anti-PEG IgG and IgM, which were over baseline in 98–99 % of unvaccinated individuals. About 3-4 % of subjects in the strongly left-skewed distribution had 15–45-fold higher values than the median, referred to as anti-PEG Ab supercarriers. Both vaccines caused significant rises of anti-PEG IgG/IgM with >10-fold rises in about ∼10 % of Comirnaty, and all Spikevax recipients. The anti-PEG IgG and/or IgM levels in the 15 vaccine reactors (3 anaphylaxis) were significantly higher compared to nonreactors. Serial testing of plasma showed significant correlation between the booster injection-induced rises of anti-S and anti-PEG IgGs, suggesting coupled anti-S and anti-PEG immunogenicity. Conclusions: The small percentage of people who have extreme levels of anti-PEG Ab in their blood may be at increased risk for HSRs/anaphylaxis to PEGylated vaccines and other PEGylated injectables. This risk might be further increased by the anti-PEG immunogenicity of these vaccines. Screening for anti-PEG Ab “supercarriers” may help predicting reactors and thus preventing these adverse phenomena. Elsevier Ltd. 2023-06-05 /pmc/articles/PMC10239905/ /pubmed/37330369 http://dx.doi.org/10.1016/j.vaccine.2023.06.009 Text en © 2023 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Kozma, Gergely Tibor
Mészáros, Tamás
Berényi, Petra
Facskó, Réka
Patkó, Zsófia
Oláh, Csaba Zs.
Nagy, Adrienne
Fülöp, Tamás Gyula
Glatter, Kathryn Anne
Radovits, Tamás
Merkely, Béla
Szebeni, János
Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG
title Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG
title_full Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG
title_fullStr Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG
title_full_unstemmed Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG
title_short Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG
title_sort role of anti-polyethylene glycol (peg) antibodies in the allergic reactions to peg-containing covid-19 vaccines: evidence for immunogenicity of peg
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239905/
https://www.ncbi.nlm.nih.gov/pubmed/37330369
http://dx.doi.org/10.1016/j.vaccine.2023.06.009
work_keys_str_mv AT kozmagergelytibor roleofantipolyethyleneglycolpegantibodiesintheallergicreactionstopegcontainingcovid19vaccinesevidenceforimmunogenicityofpeg
AT meszarostamas roleofantipolyethyleneglycolpegantibodiesintheallergicreactionstopegcontainingcovid19vaccinesevidenceforimmunogenicityofpeg
AT berenyipetra roleofantipolyethyleneglycolpegantibodiesintheallergicreactionstopegcontainingcovid19vaccinesevidenceforimmunogenicityofpeg
AT facskoreka roleofantipolyethyleneglycolpegantibodiesintheallergicreactionstopegcontainingcovid19vaccinesevidenceforimmunogenicityofpeg
AT patkozsofia roleofantipolyethyleneglycolpegantibodiesintheallergicreactionstopegcontainingcovid19vaccinesevidenceforimmunogenicityofpeg
AT olahcsabazs roleofantipolyethyleneglycolpegantibodiesintheallergicreactionstopegcontainingcovid19vaccinesevidenceforimmunogenicityofpeg
AT nagyadrienne roleofantipolyethyleneglycolpegantibodiesintheallergicreactionstopegcontainingcovid19vaccinesevidenceforimmunogenicityofpeg
AT fuloptamasgyula roleofantipolyethyleneglycolpegantibodiesintheallergicreactionstopegcontainingcovid19vaccinesevidenceforimmunogenicityofpeg
AT glatterkathrynanne roleofantipolyethyleneglycolpegantibodiesintheallergicreactionstopegcontainingcovid19vaccinesevidenceforimmunogenicityofpeg
AT radovitstamas roleofantipolyethyleneglycolpegantibodiesintheallergicreactionstopegcontainingcovid19vaccinesevidenceforimmunogenicityofpeg
AT merkelybela roleofantipolyethyleneglycolpegantibodiesintheallergicreactionstopegcontainingcovid19vaccinesevidenceforimmunogenicityofpeg
AT szebenijanos roleofantipolyethyleneglycolpegantibodiesintheallergicreactionstopegcontainingcovid19vaccinesevidenceforimmunogenicityofpeg